Study guide

22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes

Key Takeaways Explain This Topic AI

Supportive care (airway, breathing, circulation, glucose and temperature control) is the mainstay of treatment for most poisonings, and specific antidotes are used when indicated.

Activated charcoal (50 g in adults) is most useful within 1 hour of ingestion of a substance it binds, and must not be given to patients with an unprotected airway; it does not bind iron, lithium, alcohols or strong acids and alkalis.

Tricyclic antidepressant poisoning causes anticholinergic features, seizures and sodium channel blockade with a broad QRS; sodium bicarbonate is given for QRS above about 120 ms, arrhythmias or hypotension.

Organophosphate poisoning causes a cholinergic crisis (miosis, bradycardia, bronchorrhoea, bronchospasm, weakness); treat with large doses of atropine titrated to dry secretions, and consider pralidoxime.

Methanol and ethylene glycol cause a high anion gap metabolic acidosis with a raised osmolar gap; fomepizole (or ethanol) blocks alcohol dehydrogenase, and haemodialysis removes the parent alcohols and toxic metabolites.

Last updated: October 2026

  • 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes
  • Approach to the Poisoned Patient

Resuscitate: airway (intubate if GCS is low with loss of airway protection), breathing, circulation, glucose , temperature.

History: substance, amount, time, route, intent; collateral history and packaging.

Examination: look for a toxidrome, pupils, temperature, skin, bowel sounds, tone and reflexes.

Investigations: ECG (QRS, QT), blood gas with lactate, anion gap and osmolar gap, paracetamol and salicylate levels in all overdoses of unknown content, specific drug levels, creatine kinase.

Reduce absorption and enhance elimination when appropriate.

Specific antidotes.

Psychiatric assessment after recovery for intentional overdose.

Poison information services (for example national poison centres) give up-to-date advice.

Toxidromes

  • Toxidrome Typical agents Features
  • Opioid Morphine, heroin, fentanyl, methadone Miosis, respiratory depression, reduced consciousness

Sedative-hypnotic Benzodiazepines, alcohol, barbiturates Sedation with relatively normal vital signs (benzodiazepines alone), ataxia

Anticholinergic Tricyclics, antihistamines, atropine "Hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter": hyperthermia, dry skin, flushing, mydriasis, delirium, urinary retention, tachycardia

Cholinergic Organophosphates, carbamates, nerve agents Salivation, lacrimation, urination, diarrhoea, bronchorrhoea, bradycardia, miosis, fasciculation and weakness

Sympathomimetic Cocaine, amphetamines, MDMA Tachycardia, hypertension, hyperthermia, mydriasis, sweating (unlike anticholinergic), agitation, seizures

Serotonin syndrome SSRIs with MAOIs, tramadol, linezolid, MDMA Clonus (inducible, ocular), hyperreflexia, agitation, hyperthermia, diarrhoea; rapid onset

Neuroleptic malignant syndrome Antipsychotics Lead-pipe rigidity, hyperthermia, autonomic instability, raised creatine kinase; slow onset over days

Decontamination and Enhanced Elimination

Activated charcoal (50 g in adults, 1 g/kg in children): most useful within 1 hour of ingestion. Does not bind iron, lithium, alcohols, cyanide (poorly), strong acids or alkalis, or hydrocarbons. Contraindicated with an unprotected airway or bowel obstruction.

Multiple-dose charcoal enhances elimination of carbamazepine, phenobarbital, dapsone, quinine and theophylline.

Whole bowel irrigation for body packers, iron and sustained-release preparations.

Gastric lavage is rarely indicated.

Urinary alkalinisation (sodium bicarbonate) enhances salicylate elimination.

Haemodialysis removes small, water-soluble, poorly protein-bound drugs: salicylates, lithium, methanol, ethylene glycol, metformin (lactic acidosis), valproate in severe cases, and theophylline.

  • Specific Poisonings
  • Paracetamol

Hepatotoxicity results from saturation of conjugation and formation of NAPQI , which depletes glutathione (see the opioid and non-opioid analgesia section). Acetylcysteine is given according to timed plasma levels plotted on a treatment nomogram, or immediately when the time of ingestion is uncertain, staggered or the dose large. Shorter regimens (for example the 12-hour SNAP regimen used in the UK) reduce adverse reactions. Markers of severe toxicity include a rising INR, acidosis and raised creatinine; the King's College criteria guide liver transplant referral.

Salicylates

Early respiratory alkalosis (direct stimulation of the respiratory centre), then high anion gap metabolic acidosis , tinnitus, vomiting, hyperthermia, hypoglycaemia and non-cardiogenic pulmonary oedema. Treat with urinary alkalinisation (target urine pH 7.5-8.5) and correct hypokalaemia. Haemodialysis for severe toxicity, renal failure, pulmonary oedema, seizures or very high levels. If intubation is needed, maintain hyperventilation, because a rise in P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ worsens acidaemia and moves salicylate into the brain.

Tricyclic Antidepressants

Features: anticholinergic toxidrome, seizures, hypotension (alpha-blockade), and sodium channel blockade with QRS prolongation (above about 100 ms predicts seizures; above 160 ms predicts arrhythmias), right axis deviation of the terminal QRS (R wave in aVR) and ventricular arrhythmias.

Treatment: sodium bicarbonate 8.4% 50-100 mL boluses for QRS widening, arrhythmias or hypotension, aiming for an arterial pH of about 7.45-7.55; benzodiazepines for seizures; avoid class Ia and Ic antiarrhythmics and physostigmine; lipid emulsion in refractory cases.

Opioids

Naloxone 0.4 mg intravenously (or smaller titrated doses of about 0.1 mg in opioid-dependent patients to avoid acute withdrawal), repeated as needed. Its duration (about 30-90 minutes) is shorter than many opioids, so infusions and observation are needed for long-acting drugs such as methadone.

Benzodiazepines

Supportive care is usually enough. Flumazenil can precipitate seizures in mixed overdoses (especially with tricyclics) and in benzodiazepine-dependent patients, so it is not routinely recommended.

Toxic Alcohols

  • Alcohol Toxic metabolite Features
  • Methanol Formic acid Visual disturbance, blindness, acidosis
  • Ethylene glycol Glycolic and oxalic acids Renal failure, calcium oxalate crystals, hypocalcaemia

Both cause a raised osmolar gap early and a high anion gap metabolic acidosis later. Treat with fomepizole (or ethanol) to block alcohol dehydrogenase, haemodialysis, and folate (methanol) or thiamine and pyridoxine (ethylene glycol).

Carbon Monoxide

Binds haemoglobin with about 240 times the affinity of oxygen, shifts the dissociation curve to the left and inhibits cytochrome oxidase. Pulse oximetry over-reads saturation; measure carboxyhaemoglobin by co-oximetry. Treat with 100% oxygen (half-life about 4-5 hours in air, about 75 minutes on 100% oxygen); hyperbaric oxygen may be considered for severe poisoning or pregnancy.

Cyanide

Smoke inhalation (burning plastics), sodium nitroprusside and industrial exposure. Cyanide inhibits cytochrome c oxidase , causing histotoxic hypoxia, severe lactic acidosis and a high venous oxygen saturation. Treat with hydroxocobalamin 5 g intravenously (forms cyanocobalamin), or sodium thiosulphate.

Organophosphates

Inhibit acetylcholinesterase, causing a cholinergic crisis with muscarinic (bronchorrhoea, bronchospasm, bradycardia, miosis) and nicotinic (fasciculation, weakness, paralysis) effects.

Atropine in doubling doses (start 1-2 mg) every 5 minutes until the chest is clear, heart rate above about 80/min and systolic pressure above 80 mmHg; large total doses may be needed.

Oximes (pralidoxime) can reactivate the enzyme if given before "ageing".

Avoid suxamethonium (prolonged block); staff should use protective equipment.

An intermediate syndrome of proximal and respiratory weakness can occur 1-4 days later.

Cardiovascular Drugs

Poison Treatment

Digoxin Digoxin-specific antibody fragments for life-threatening arrhythmias or potassium above about 5-6 mmol/L; correct hypokalaemia and hypomagnesaemia

Beta-blockers Atropine, glucagon, high-dose insulin euglycaemic therapy (for example 1 unit/kg bolus then infusion with glucose), vasopressors, pacing, lipid emulsion, ECMO

  • Calcium channel blockers Calcium, high-dose insulin euglycaemic therapy, vasopressors, lipid emulsion, ECMO
  • Other Important Antidotes
  • Poison Antidote
  • Iron Desferrioxamine
  • Methaemoglobinaemia (for example from dapsone, local anaesthetics) Methylene blue 1-2 mg/kg
  • Heparin Protamine
  • Warfarin Vitamin K and prothrombin complex concentrate
  • Local anaesthetic toxicity 20% lipid emulsion
  • Malignant hyperthermia, some cases of neuroleptic malignant syndrome Dantrolene
  • Isoniazid Pyridoxine